APPOINTMENTS/EMPLOYMENT

 

Acedemic Appointments:

1978 - 1982 Clinical Instructor of Psychiatry, Tufts-New England Medical Center, Boston, Ma.                  

1982 - 1984 Instructor of Psychiatry, Cornell University Medical College, New York, N.Y.

1984 - 1985 Assistant Professor of Psychiatry, Cornell University Medical College, New York, N.Y.

1985 - 1987 Instructor of Psychiatry, Mount Sinai School of Medicine, New York, N.Y.

1988 - 1992 Assistant Professor of Psychiatry, Mount Sinai School of Medicine, New York, N.Y.

1992 - 2017 Associate Professor of Psychiatry and Pediatrics, Mount Sinai School of Medicine, New York, N.Y.

2017 - Present Professor of Psychiatry and Pediatrics, Icahn School of Medicine at Mount Sinai; New York, NY

 

Hospital Appointments:

1982 - 1983 Staff Psychiatrist - Adolescent and Eating Disorders Unit,

New York Hospital - Westchester Division, White Plains, N.Y.

1983 - 1985 Assistant Unit Chief, Adolescent and Eating Disorders Unit, New York Hospital - Westchester Division, White Plains, N.Y.

1985 - 1992 Director, Child Psychiatry Inpatient Unit, Mount Sinai Hospital, New York, N.Y.

1988 - 1997; Director of Residency Training in Child and Adolescent Psychiatry,

2000-2002 Mount Sinai School of Medicine, New York, N.Y.

1992 - 2014 Director, Division of Child and Adolescent Psychiatry, Mount Sinai Medical Center; New York, N.Y.

2014 Director, Division of ADHD and Learning Disorders; Mount Sinai Medical Center; New York, N.Y.

2014 Director, Pediatric Psychopharmacology; Mount Sinai Health System

2014 Director, Student/Trainee Mental Health Service; Mount Sinai Medical Center; New York, NY

 

GAPS IN EMPLOYMENT - None

 

EDUCATION

 

1973   B.A. University of Rochester, Rochester, N.Y.

1977   M.D. University of Rochester, Rochester, N.Y.

 

POST DOCTORAL TRAINING:

1977 - 1978 Intern in Psychiatry, Tufts-New England Medical Center, Boston, Massachusetts

1978 - 1980 Resident in General Psychiatry, Tufts-New England Medical Center, Boston, Massachusetts

1980 - 1982 Resident in Child Psychiatry, Tufts-New England Medical Center, Boston, Massachusetts

 

CERTIFICATION    

 

1982 American Board of Psychiatry and Neurology, General Psychiatry, Certificate # 24132

1984 American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry,   Certificate # 1871

 

LICENSURE   

 

1978 Massachusetts (currently inactive) [#44174]

1982   New York State Medical License [#150793]

1982 DEA [#AN2033354]

2002 - 2014 New York State Research License [#040 0825]

HONORS/AWARDS

 

1973 Phi Beta Kappa

1990 "N+1" Fellow: Annual Meeting, Professors of Child and Adolescent Psychiatry

1997 - Present        Best Doctors in NY

2002 Hulse Award: New York Council on Child and Adolescent Psychiatry (Lifetime achievement in Child and Adolescent Psychiatry in New York)

2004, 2005 AACAP Outstanding Mentor Award - Given for mentorship in the Jeanne Spurlock medical student fellowship program

2003 - Present        Castle – Connolly Top Doctors: New York Metro Area

2003, 2014 - 2015, New York Magazine: Best Doctors

2017 - Present

2008        Newsday: Top Doctors on Long Island (online)

2009 AACAP Outstanding Mentor Award: Given for mentorship in the AACAP/NIDA   K-12 Physician Scientist Program in Substance Abuse.

2009 Best poster: 2nd International ADHD Congress; Vienna, Austria. “Do Symptomatic and Functional Change Predict Treatment Preference? Mid-Term Results of a Randomized, Double Blind, Crossover Study of OROS Methylphenidate and Atomoxetine” (Newcorn, Marcus, Stein, Bedard)

2013 - Present        New York Times Magazine: New York Super Doctors

2014 - Present      Best Doctors in America

2014   CHADD Hall of Fame (Lifetime contributions to the ADHD field)

2014 Best Poster: American Society of Clinical Psychopharmacology Annual Meeting; Hollywood, Fla. “Neurobiological Basis of Response to Lisdexamfetamine (Vyvanse®) in Adults with ADHD” (Duhoux, Schulz, Krone, Bédard, Pedraza, Adler, White, Blair, Newcorn)

2015 4D Technology Development Award (Juan Pedraza; Jeffrey Newcorn); Icahn School of Medicine at Mount Sinai.  Development and pilot testing of a novel objective measure of ADHD pathophysiology and treatment

2016 Best Poster: American Professional Society for ADHD and Related Disorders (APSARD) Annual Meeting; Washington, DC. “Reward Processing in Drug-Naïve Youth with Various Risks for Substance Use Disorders” (Ivanov, Li, Schultz, Phillips, Krone, Fan, Newcorn)

2017 Teacher of the Year Award; Department of Psychiatry; Division of Child and Adolescent Psychiatry; Icahn School of Medicine at Mount Sinai

2018 Elaine Schlosser Lewis Award for Research in Attention Deficit Disorder (best paper on ADHD by a child psychiatrist published in JAACAP in 2017-2018); “Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine”

 

PATENTS  None

 

OTHER PROFESSIONAL ROLES

 

Editorial Board Membership:

1991 - 2000 Journal of Learning Disabilities

1998 - Present Journal of Child and Adolescent Psychopharmacology (Deputy Editor for Clinical Pharmacology; 2016-Present)

1998 - Present Journal of Attention Disorders

1998 - Present Journal of Abnormal Child Psychology

2001 - 2007 Journal of the American Academy of Child and Adolescent Psychiatry

2005 - Present Current Pediatric Reviews    

2007 - 2011 Journal of ADHD and Related Disorders

2018 - Present CNS Drugs

 

Other Editorial Activities:

1991 - 1993 Editor, Scientific Proceedings of the Annual Meeting: American Academy of Child and Adolescent Psychiatry.

2000 - 2004 Section editor (Child Psychiatry): Current Psychiatry Reports

2000 Guest editor: CNS Spectrums; special issue on ADHD.

2003 - 2004 Editor: Mount Sinai School of Medicine Reports on ADHD

2004 Guest editor: CNS Spectrums; special issue on ADHD

 

Ad Hoc Reviewer (Journal):

Beginning date Journal

1989 Journal of the American Academy of Child and Adolescent Psychiatry

1994 Psychosomatics

1997   Journal of Child and Adolescent Psychopharmacology

1998 Mental Retardation and Developmental Disabilities Research Reviews

2002 Archives of General Psychiatry (JAMA Psychiatry)

2003 American Journal of Psychiatry

2003 Biological Psychiatry

2003 Pediatrics

2003 Journal of Child Psychiatry Psychology and Allied Professions

2003 Expert Opinion on Investigational Drugs

2004 Expert Opinion on Pharmacotherapy

2004 Acta Psychiatrica Scandinavica

2004 Journal of Clinical Child Psychology

2005 Behavioral and Brain Function

2005 Journal of Clinical Psychiatry

2005 Expert Review of Neurotherapeutics

2007 Archives of Pediatrics and Adolescent Medicine

2007 Psychological Medicine

2007 European Child Psychiatry

2008 Journal of Abnormal Child Psychology

2009 Comprehensive Psychiatry

2010 CNS Spectrums

2010 Psychiatry Research

2011 Child and Adolescent Mental Health

2011 Developmental Science

2012 Neuropsychopharmacology

2012 Journal of Pediatrics

2012 European Neuropsychopharmacology

2012 Japanese Psychological Research

2012 Human Brain Mapping

2012 Psychiatry Research, Neuroimaging

2012 CNS Drugs

2013 The Lancet

2013 Cerebral Cortex

2013 Molecular Psychiatry

2013 JAMA

2013 Molecular Neurobiology

2013 Neuropsychiatric Genetics

2013 BMC Psychiatry

2014 The Lancet Psychiatry

2014 Neuroimage: Clinical

2015 Abnormal Psychology

2015 Harvard Review of Psychiatry

2015 Journal of Clinical and Experimental Neuropsychology

2016 Translational Psychiatry

2016 American Journal on Addictions

2016 Journal of Psychiatric Research

2016 Journal of Psychopharmacology

2017 Nature Communications

2017 Journal of Clinical Psychopharmacology

2018 BMJ Evidence-Based Medicine

2018 Journal of Medical Economics

2019 JAMA Network Open

2019 World Journal of Biological Psychiatry

2019 Pediatric Drugs

2019 European Psychiatry

2019 Biological Psychiatry: Cognitive Neuroscience and Neuroimaging

2019 The Medical Letter

2020 Lancet Child and Adolescent Health

2020 Psychopharmacology

2021 Development and Psychopathology

2021 The Lancet Regional Health – Europe

2021 Molecular Psychiatry

2021 Developmental Cognitive Neuroscience

 

Ad Hoc Reviewer (Other):

Beginning Date Organization or Institute

1993 William T. Grant Faculty Scholars Program

1994 Leon Lowenstein Foundation

1998 - 1999 Klingenstein Third Generation Foundation (review of portfolio)

2001 - Present National Institute of Mental Health

2012 - Present Swiss National Science Foundation

2012 Netherlands Organisation for Scientific Research (NWO)

2012 ZonMw - Dutch Organisation for Health Research and Development

2013 Austrian Science Fund

2014 UK Medical Research Council (MRC)

2014 Mount Sinai G2R Program

 

Industry Advisory or Data Safety Boards:

1999 - 2008, 2011 Ortho-McNeil-Janssen Pharmaceuticals

(previously Alza Pharmaceuticals, McNeil Pediatrics)

2000 Sepracor Pharmaceuticals

2001 - 2008 Novartis Pharmaceuticals  

2001 - 2011 Eli Lilly

2004 - 2005 Celltech/UCB Pharmaceuticals

2004 - Present Shire Pharmaceuticals (now Takeda (2019))

2004 Bristol Myer Squibb

2005 - 2006 Cepahalon

2005, 2007 Sanofi-Aventis

2006 Pfizer

2006 Cortex

2007, 2014 Lupin

2008 Abbott

2008, 2011 - 2016 Biobehavioral Diagnostics (currently Pearson)

2009 Astra-Zeneca

2009 Schering-Plough

2011 - 2017 Alcobra

2011, 2015 - 2016 Neos Therapeutics

2011 Shionogi

2012 Otsuka

2012 - 2016 GencoSciences

2013 - 2019 Sunovion (DSMB)

2013, 2015 - 2018 Enzymotec

2014                  Neurovance

2014 - 2016; 2019         Ironshore

2015 - Present            Rhodes  

2015            Cerecor

2016 - Present       NLS

2016 - Present              Supernus

2016, 2018 – 2020         Arbor

2016, 2018, 2020           Medice

2016 - 2019                   Akili Interactive

2017, 2020               Lundbeck

2017                 KemPharm

2017, 2020-Present       Cingulate Therapeutics

2018                     Pfizer (DSMB)

2019 - Present              Adlon Therapeutics

2019 - Present             OnDosis

2020          Eisai

2020                       Mind Medicine

2020  - Present              Myriad Neuroscience

2020 - Present            Corium

 

Other Advisory or Consulting Activity:

2015 - Present National Football League (therapeutic medication use program)

2000 - Present               Klingenstein Third Generation Foundation Advisory Board

                                   (Chair: 2007 – Present)

 

Board Examiner:

1991 - 1995 American Board of Psychiatry and Neurology/General Psychiatry

1997 - 1999 American Board of Psychiatry and Neurology/ Child and Adolescent Psychiatry

RESEARCH PROFILE

 

I am a highly-regarded researcher in the areas of Attention-deficit/Hyperactivity Disorder (ADHD), aggression, descriptive psychopathology of child and adolescent disorders, and child and adolescent psychopharmacology. My work spans both clinical and translational topics. I was a member of the steering committee (Chair, 2000; Co-Chair, 1999 and 2001) of the NIMH-funded multicenter study “Multimodal Treatment of Children with ADHD (MTA)”, which is arguably the most influential study of ADHD treatment ever conducted (e.g., the primary MTA outcome paper, published in 1999, has been cited over 3000 times). I was the primary investigator on a NIMH-funded ADHD Research Infrastructure Network, which brought together an illustrious team of investigators to conduct and develop studies devoted to understanding the neurobiology of ADHD, and have been the principle investigator or co-investigator on numerous NIMH-funded grants that examine the clinical, genetic, neuroanatomic and neurophysiologic basis of ADHD and its treatment. I have been an active research mentor, having served as primary or secondary mentor on eight NIMH training grants (K awards). I direct an active clinical trials program, and have studied many of the newer medication treatments for ADHD. I also provide consultation to many pharmaceutical companies regarding the development and investigation of novel medications for ADHD. My research has been recognized for excellence on several occasions, most recently as winner of the Elaine Schlosser Lewis award for reseach in attention deficit disorder. My current research focuses on the clinical and neurobiological basis of response to ADHD treatments, with a particular focus on stimulant vs. non-stimulant treatment mechanisms, with a principal objective of ultimately being able to match treatment selection to individual patient characteristics.    

 

CLINICAL PROFILE

 

I am a highly regarded clinician with special expertise in the diagnosis and treatment of ADHD, and pediatric psychopharmacology. I am consulted by patients from across the country and internationally. I have been a Castle Connolly “Best Doctor” continuously since 2003. I have been listed as a Best Doctor in New York Magazine six times (2003, 2014 – 2015, and 2017 - 2020). I was a member of the DSM-IV advisory committees on child and adolescent disorders and disruptive behavior disorders, a consultant to the American Academy of Pediatrics Task force for Coding Mental Health in Children, and a member of the steering committee for the DSM-IV for Primary Care, Child and Adolescent Version. I am also a nationally recognized educator and mentor. I have been an examiner for both the Child and Adolescent Psychiatry and General Psychiatry boards. I served as Chair, and then Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Training and Education from 2002 – 2005, and I was the director of the AACAP Board Review Course in 2002. I have been recognized by AACAP on several occasions for mentorship of medical students and junior faculty. Finally, I have been a highly successful clinical administrator, having directed the Division of Child and Adolescent Psychiatry at Mount Sinai for 22 years, and building it from a small clinical program with a primarily local reputation to a major academic program recognized both nationally and internationally.

 

IMPACT

 

I am one of the most published child and adolescent psychiatrists nationally, with over 250 peer-reviewed publications, many in highly influential journals, and over 100 additional papers and chapters in textbooks, including most of the leading textbooks in the field. The impact of these publications is reflected in my high citation index (h index 94; 51 in the last 5 years; i10-index 236; 171 in the past 5 years). I am (or have been) an editorial board member of several of the leading child psychiatry and psychology journals, and am currently Deputy Editor for Clinical Pharmacology, Journal of Child and Adolescent Psychopharmacology; in addition, I conduct ad hoc reviews for most of the leading psychiatry journals, several of the most influential general medical journals, as well as NIMH. I have developed a national and international reputation in the area of ADHD psychopathology, neurobiology and treatment, as well as pediatric psychopharmacology more broadly, and I am a frequent presenter or invited lecturer on these topics at leading national and international meetings. I have been an advisory board member of the Klingenstein Third Generation Foundation for over 15 years, and have been the Chair of the Advisory Board continuously since 2007. I have been a member of the Board of Directors of the American Professional Society for ADHD and Related Disorders (APSARD) since its inception in 2008. I was chair of the Scientific Program Committee from 2014 – 2018, President-elect from 2018-202, and began my term as President in January, 2020. I have been a member of the Scientific Program Committee for the 5^th, 6^th and 7^th International ADHD Congresses (2015 – Present), and have served on the Organizing Committee of the 2nd and 3^rd International Symposia on ADHD; Tel Aviv, Israel (March, 2018). My impact in the field has been recognized by the New York Council on Child and Adolescent Psychiatry (Hulse award for lifetime achievement, 2002) and CHADD (CHADD Hall of Fame, 2014).  

 

GRANTS, CONTRACTS, FOUNDATION SUPPORT

PAST GRANTS

Past Awards: Federal   

1. Project Name:  "Validation of Inattentive and Aggressive ADHD Subtypes"       P.I.:  Jeffrey M. Halperin, Ph.D.

      Funding Source:  NIMH #RO1 MH46448-01

      Funding Period: 8/1/90 - 7/31/93

      Annual Direct Costs:  $ 435,973

      Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 15%

 2. Project Name:   "Multimodal Treatment of Children with ADHD"

      P.I.:  Laurence Greenhill, M.D. (New York Site)

      Funding Source:  NIMH (#UO1 NH 50554-01)

      Funding Period: 9/1/92 - 8/30/97

      Total Cost:  $ 1,755,500

      Annual Direct Costs:  $ 394,473

      Percent Effort for Dr. Newcorn (principal Co-P.I.; Mount Sinai P.I.):

      20% in years 1, 5; 30% in years 2-4; 10% in years 5- 6

3. Project Name:  "Serotonergic Function in Childhood Aggression"

P.I.:  Jeffrey M. Halperin, Ph.D.

     Funding Source: NIMH (#RO1 NH 46448-04A1)

     Funding Period: 05/01/94 - 04/30/98

      Total Cost:  $ 976,147

      Annual Direct Costs:  $ 142,814

      Percent Effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 10%

4.    Project Name:  "Pharmacotherapy of Adolescent Body Dysmorphic Disorder"

     P.I. Eric Hollander, M.D.

     Funding Source: NIMH

     Funding Period: 3/15/99 - 2/28/03

     Annual Direct Costs:  $ 66,578

Percent effort for Dr. Newcorn (Co-I): 5%

5. Project Name: “Stimulant Drug Treatment of ADHD Inattentive Type”

      P.I.: Mary Solanto Gardner, Ph.D.

Funding Source: NIMH

Funding Period: 09/30/00-09/29/03

Total Costs: $635,625

Percent Effort for Dr. Newcorn (Co-I): 10%

6. Project Name: “Heterogeneity of ADHD: Predictors of Adolescent Outcome”

PI: Jeffrey Halperin, Ph.D.

Funding Source: NIMH 1RO1 MH 60698-02

Funding Period: 12/01/00-11/30/2005

Total Costs: $310,270

Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 10%  

7.    Project Name:  “Delineation of ADHD Subtypes and Mechanisms” (ADHD Network)

PI: Jeffrey Newcorn, M.D.

Funding Source: NIMH 1 R21 MH066360-01

Funding Period: 8/9/02-7/31/06

Annual Direct Costs: $175,000

Percent effort for Dr. Newcorn: 10%

8.    Project Name: “Creating a Collaborative Field Research Organization”

PI: Claude Chemtob, Ph.D.

Funding Source: NIMH 1 R24 MH63910-01A1

Funding Period: 9/1/02-5/31/08

Total Annual Direct Cost:  $400,000

Percent effort for Dr. Newcorn (Co-I): 15%

9. Project Name: “Parent and Child Trauma Service to Reduce Sexual Risk”

PI: Annette Hernandez, PhD

Funding Source: NIMH R34 MH75626-01

Funding Period:  7/1/06 – 6/30/09

Total cost: $375,000

Percent effort for Dr. Newcorn (Co-I): 5%

10.   Project Name: “Brain Dopamine Function in Adults with ADHD”

PI: Gene-Jack Wang, M.D.

Funding Source: NIMH R01MH66961-01

Funding Period:  7/31/03- 7/30/09

Total Cost: $94,010 (Mount Sinai subcontract)

Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 5%

11. Project Name: “Measuring and Predicting Response to Atomoxetine and       Methylphenidate”

PIs (collaborative R01): Jeffrey Newcorn, M.D. (Mount Sinai PI) and Mark Stein, Ph.D.

Funding Source: NIMH 1R01 MH070935-01A1

Funding Period: 12/1/04 - 6/30/11

Total Cost: $2,561,496

Percent effort for Dr. Newcorn:  39%  

12. Project Name: “Methylphenidate and Atomoxetine in ADHD: fMRI Measures of Mechanisms and Response”

PI: Jeffrey Newcorn, MD

Funding Source: NIMH 3R01MH070935-02S1

Funding Period: 1/1/06-6/30/11

Total cost: $841,000

Percent effort for Dr. Newcorn: 10%

13.   Project Name: “Brain Activation in Preadolescents with High versus Low Risk for Subsequent Substance Abuse”

PI: Iliyan Ivanov, MD

Funding Source: NIDA (through AACAP) 1 K12 DA000357-06A1

Funding Period:  7/1/05-5/31/10

Total cost: $948,226

Percent effort for Dr. Newcorn: 2% (Primary mentor)

14.   Project Name: “Dependence of the Development of Attention on Genotype”

PI: John Fossella, PhD

Funding Source: NIMH 1-K01-MH074573-01A1

Funding Period: 1/1/07 – 4/30/11

Total cost: $716,759

Percent effort for Dr. Newcorn: 2% (Primary mentor)

15.   Project Name: “Integrative approach to functional neuroimaging of ADHD”

PI: Kurt Schulz, PhD

Funding Source: NIMH 1 K01 MH070892-01

Funding Period:  7/1/05 – 6/30/10

Total cost: $948,226

Percent effort for Dr. Newcorn: 2% (Secondary Mentor)

16.   Project Name: “Impact of Stimulant Treatment on Neural Reward Circuitry Functioning in ADHD

PI: Olga Berwid, PhD

Funding Source: NIDA (subcontract through CUNY)

Funding Period: 12/1/08-09/30/11

Total Direct Cost: $150,000

Percent effort for Dr. Newcorn: 3% (co-investigator)

17.   Project Name: “Activation of Neuronal Networks Related to Risk for Addiction: A Pilot fMRI Study”

PI:  Iliyan Ivanov, MD

Funding Source: NIDA

Funding Period:  2/1/08-2/28/11

Total Direct Cost: $150,000

Percent effort for Dr. Newcorn: 3% (co-investigator)

18.       Project Name: “ADHD: Neural Correlates of Adult Outcome”

      PI: Jeffrey Halperin, PhD

Funding Source: NIMH 2R01MH060698-06A2

Funding Period:  2/01/07 – 1/31/13 (open now for data analysis only)   

Total cost: $1,842,230

Percent effort for Dr. Newcorn (Co-I): 5%

19. Project Name: Piloting Treatment with Insulin-Like Growth Factor-1 in Phelan-McDermid

Syndrome

PI: Alexander Kolevzon, MD

Funding Source: NIMH (R34 MH100276-01)

Funding Period: 7/19/13 - 4/30/16

Total Direct Cost: $450,000

Percent effort for Dr. Newcorn: 1% 

 

20.   Project Name: Imaging Stimulant and Non-stimulant Treatments for ADHD: A Network- basedApproach

PI: Jeffrey Newcorn, MD and Kurt Schulz, PhD (Co-PIs)

Funding Source: NIMH (1R01MH095766-01A1)

Funding Period: August 10, 2012 – March 31, 2018

Total Cost: $3,176,153

Percent effort for Dr. Newcorn: 40%

 

Past Awards: Foundation                   

1.   Project Name: "DSM-IV Field Trial for Disruptive Behavior Disorders"

      P.I.:  Benjamin B. Lahey, Ph.D.

      Funding Source:  NIMH, subcontract through A.P.A.

      Funding Period:  7/1/90 - 6/30/92

      Total Cost:  $ 8,125

      Percent Effort for Dr. Newcorn:  10% (Director; Mount Sinai Child Inpatient Site)

2. Project Name: "Adjustment Disorders - Defining Characteristics and Discriminant Validity"

      Co-Investigators: Juan Mezzich, M.D., Ph.D. and James J. Strain, M.D.

      Funding Source:  MacArthur Foundation

      Funding Period:  7/1/90 - 6/30/92

      Total Cost:  $ 6,000      

3. Project Name: "The Relationship of Central 5-HT, Aggression and Environmental Factors to Adolescent Outcome in Children with ADHD: A Prospective Follow-up Study"

P.I. Jeffrey M. Halperin, Ph.D.

     Funding Source: W. T. Grant Foundation

     Funding Period: 12/1/97 - 11/30/00

     Annual Direct Total Costs: $283,134

     Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 3%

4. Project Name: “Functional MRI in Predominantly Inattentive and Combined Subtypes of ADHD”

Co-PIs: Mary Solanto-Gardner, Ph.D.; Jeffrey Newcorn, M.D.

Funding Source: Elaine Schlosser Lewis Foundation

Funding Period: 1/02 - 1/03

Annual Direct Costs: $25,000

Percent effort for Dr. Newcorn: As needed

5. Project Name: The neural correlates of visual-spatial working memory in children and adolescents with and without ADHD: An fMRI study of brain activation

PI: Anne Claude Bedard, PhD; Jeffrey Newcorn, MD (Mentor), Jeffrey Halperin, PhD (Mentor), Kurt Schulz, PhD (Mentor)

Funding Source: The Klingenstein Third Generation Foundation

Funding Period: 2010-2012

Total Cost: $60,000

6. Project Name: Improving identification of Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function in Parents of Children Diagnosed with ADHD Using Objective Measures

PI: Juan Pedraza, MD; Jeffrey Newcorn, MD (Co-PIs)

Funding Source: APSARD/Pond Family Award

Funding Period: 2012 - 2013

Total Cost: $20,000

Percent effort for Dr. Newcorn: 5%

Past Awards: Pharmaceutical (Investigator initiated)

1.   Project Name: “Mechanisms of Action of Methylphenidate and Atomoxetine: fMRI Measures of Brain Activation in Response to Executive Function and Inhibitory Control Tasks”

PI: Jeffrey Newcorn, MD

Funding Source: Eli Lilly & Company

Funding Period: 5/7/02-4/30/03

Annual Direct Costs: $115,586

Percent Effort for Dr. Newcorn: 3%

2.   Project Name: “Neurophysiology of ADHD and Comorbid Anxiety Disorders: fMRI Measures of Brain Activation in Response to Attentional Executive Function and Inhibitory Control Tasks Pre- and Post-Atomoxetine Treatment”

PI:  Jeffrey Newcorn, M.D.

Funding Source: Eli Lilly & Company

Funding Period: 11/25/02-10/31/03

Total Cost: $61,921

Percent Effort for Dr. Newcorn: 3%

 

3. Project Name: “Medication Effects on Brain Activation During Inhibitory Control in ADHD:  An fMRI Study”

PI: Jeffrey Newcorn, M.D.

Funding Source: Eli Lilly and Co.

Funding Period: 2/29/04-3/1/07 (In rollover; open for data analysis only)

Total Cost:  $91,800

Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 3%

4. Project Name: “Clinician Administered Ratings of Symptoms in Patients with ADHD”

PI:  Lenard Adler, MD

Funding Source: Eli Lilly (subcontract from NYU)

Funding Period:  9/30/05-9/29/09

Total costs: $16,200

Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): As needed

5.   Project Name: “Comparison of Self and Clinician Administered Ratings of Symptoms in Patients with ADHD”

PI:  Lenard Adler, MD

Funding Source: Shire Pharmaceuticals (subcontract from NYU)

Funding Period: 5/26/06 – 5/25/10

Total Subcontract Cost:  $20,640

Percent effort for Dr. Newcorn (Co-I; Mount Sinai P.I.): 1%

 

6.    Project Name: Neurobiological Basis of Response to Vyvanse in Adults with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

PI:  Jeffrey Newcorn, MD and Kurt Schulz, PhD

Funding Source: Shire Pharmaceuticals (investigator initiated trial)

Funding Period: 3/24/2010-3/23/2014

Total Cost: Approximately $575,000

Percent effort for Dr. Newcorn: 15%

7. Project Name: “Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment”

PI: Jeffrey Newcorn, MD and Kurt Schulz, PhD

Funding Source: Shire Pharmaceuticals (investigator initiated trial)

Funding Period:  11/3/2009 – 11/2/2014

Total Cost:  $589, 384

Percent effort for Dr. Newcorn: 25%

 

8. Project Name:  Efficacy of Lisdexamfetamine in Adults with ADHD and Sluggish Cognitive Tempo

Co-PIs:  Lenard Adler MD and Jeffrey Newcorn, MD (Funded as subcontract through NYU)

Funding Source:  Shire Pharmaceuticals

Funding Period:  2015 - 2018

Total cost:  $700,000 (~half at Mount Sinai)

Percent Effort for Dr. Newcorn: As Needed

9. Project Name:  Neurobiological Basis of Response to Vayarin in Adults with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

PI: Jeffrey Newcorn, MD

Funding Source: Enzymotec

Funding Period: January 1, 2015 – December 31, 2018

Total cost: $518,356

Percent Effort for Dr. Newcorn: As Needed

 

Past Awards: Consultant

       1.    Project Name: "Enhancing ADHD Treatment Effectiveness by

            Pediatrics and Schools"

     P.I.: Mark Wolraich, M.D.

     Funding Source: NIMH

   Funding Period: 1998 – 2003

2. Project Name: “Follow-up of the Multimodal Treatment Study of Children with ADHD”

P.I.: Laurence Greenhill, M.D. (Columbia site)

   Funding Source: NIMH contract

     Funding Period: 2000-2005 (now in extension only)

    (Dr. Newcorn remains on Steering Committee as co-investigator)

 

CURRENT GRANTS

Current Awards: Federal

1. Project Name: Reward Systems and Food Avoidance in Adolescents with Low Weight Eating Disorders.   

PI: Tom Hildebrandt, PhD

Funding Source: NIMH (R01)

Funding Period: August 19, 2016 – May 31, 2020

Total Direct Cost: $1,541,339

Percent effort for Dr. Newcorn: 5%

2. Project Name: CES1 Genetic Variation Influences Methylphenidate in ADHD

PI: John Markowitz, Pharm D (J Newcorn is coordinating clinical Co-I and Mount Sinai PI)

Funding Source: NICHD subcontract through University of Florida (R01)

Funding Period: 08/16/2018 – 07/31/2023

Total Annual Direct Cost: $575,284

Percent effort for Dr. Newcorn: 20%

3. Project Name: Stimulant vs. non-stimulant treatments and reward processing in drug-naive youth at SUD risk                

PI: I Ivanov/J Newcorn (J Newcorn is contact PI)

Funding Source: NIDA R21 DA045218-01A1            

Funding Period: 9/14/18 – 8/31/2020

Total Annual Direct Cost: $150,000

Percent effort for Dr. Newcorn: 12%

4. Project Name: Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder (Pending (Impact score 17))

PI: I Ivanov/J Newcorn (J Newcorn is contact PI) Funding Source: NIDA (R21DA046029)

Funding Period: 04/01/19-03/31/21

Total Annual Direct Cost: $150,000

Percent effort for Dr. Newcorn: 12%

Current Awards: Foundation

1. Epigenetics of Methylphenidate Adverse Effects and Pharmacokinetics in Children with ADHD

PI: Tanya Froehlich, MD (J Newcorn is Mount Sinai PI)

Funding Source: Cincinnati Children’s Hospital Medical Center

Dates: 2018-2021

Costs: $2,000 for Mount Sinai subcontract

Percent Effort for Dr. Newcorn: As Needed

Current awards: Pharmaceutical (Investigator initiated) - None                                              

CLINICAL TRIALS PARTICIPATION

Current awards:

1. Project Name: “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment (CHIME 302).”

P.I.:  Jeffrey H. Newcorn, M.D.